Vanqua Bio is helping usher in a new era of hope for the millions of people living with neurodegenerative diseases. Our unique drug-development approach is designed to overcome longstanding challenges in the neuroscience field by capitalizing on the power of human genetics to identify genes that cause or increase the risk of neurodegenerative disease. We leverage novel, proprietary research tools and in vitro modeling of disease, based on patient-derived neuronal cells, to develop transformative therapies that slow or stop the progression of Parkinson’s disease (PD), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Gaucher disease (GD).
Location: United States, Illinois, Chicago
Employees: 11-50
Total raised: $85M
Founded date: 2019
Investors 5
| Date | Name | Website |
| 15.01.2022 | Omega Fund... | omegafunds... |
| - | Avoro Capi... | avorocapit... |
| - | OrbiMed | orbimed.co... |
| 16.08.2024 | SymBiosis | symbiosis.... |
| - | Pontifax V... | pontifax.c... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.09.2021 | Series B | $85M | Omega Fund... |
Mentions in press and media 8
| Date | Title | Description |
| 18.09.2024 | Vanqua Bio to Participate in Upcoming Scientific Conferences | CHICAGO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced today that it will participate ... |
| 20.06.2024 | Vanqua Bio to Present at Inaugural GBA1 2024 Meeting | CHICAGO, June 20, 2024 (GLOBE NEWSWIRE) -- Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for the treatment of neurodegenerative diseases, announced today that it will participate i... |
| 13.03.2024 | Vanqua Bio to Present at the Stifel 2024 CNS Days Conference | - |
| 24.03.2022 | Vanqua Bio to Present at the Stifel 2022 CNS Day Conference | CHICAGO, March 24, 2022 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the Stifel 2022 CNS Day Conference, which is being held virtually March 28-29. “Vanqua Bio was founded to transform a cutting-edge t... |
| 14.09.2021 | Vanqua Bio snags $85M series B to vanquish Parkinson's, Gaucher, ALS and Alzheimer's | As its name suggests, Vanqua Bio wants to vanquish neurodegenerative diseases like Parkinson's and Alzheimer's. Now, the biotech has $85 million in series B funds from a series of venture firms and Big Pharma Eli Lilly to start human trials... |
| 14.09.2021 | Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases | – Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies – – Lead program targets Parkinson’s disease and all forms of Gaucher disease – C... |
| - | Vanqua Bio | “Home Page - Vanqua Bio” |
| - | Neuro startup Vanqua Bio emerges with $85M and a first focus on Parkinson’s | Vanqua Bio, a biotech startup developing new treatments for neurodegenerative disorders, has launched with $85 million in funding as it plots a course to bring its lead program into human testing. Parkinson’s disease is the initial focus of... |